Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 17Ovarian Neoplasms 15Triple Negative Breast Neoplasms 10Neoplasms 8Fallopian Tube Neoplasms 8Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Brain Neoplasms 4Astrocytoma 4Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Gliosarcoma 3Glioblastoma 3Colonic Neoplasms 3Breast Neoplasms, Male 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2

Interventions

Capecitabine 4Radiation 3spartalizumab 2Oxaliplatin 2veliparib 1toripalimab 1tislelizumab 1sintilimab 1peposertib 1XELOX 1Radiotherapy 1Irinotecan 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Locally Advanced Rectal Cancer × veliparib × Clear all
NCT01589419 2017-11-20

A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer

AbbVie

Phase 1 Completed
32 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡